NCT03117998View on ClinicalTrials.gov

Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

March 5, 2021

Study Completion Date

March 5, 2021

Conditions
Type1 Diabetes Mellitus
Interventions
BIOLOGICAL

REMD-477

Administered as repeated SC doses in subjects with Type 1 Diabetes

BIOLOGICAL

Placebo Comparator

Administered as a repeated SC doses in subjects with Type 1 Diabetes

Trial Locations (11)

30318

Atlanta Diabetes Assoicates, Atlanta

63110

Washington University School of Medicine, St Louis

75230

Dallas Diabetes Research Center, Dallas

78229

Clinical Trials of Texas, San Antonio

78749

Texas Diabetes & Endocrinology, Austin

80045

University of Colorado, Denver/Barbara Davis Center for Diabetes, Aurora

92025

AMCR Institute, Escondido

92037

Altman Clinical and Translational Research Institute, San Diego

94598

Diablo Clinical Research, Walnut Creek

94904

Marin Endocrine Care & Research, Greenbrae

98057

Rainer Clinical Research Center, Renton

All Listed Sponsors
lead

REMD Biotherapeutics, Inc.

INDUSTRY

NCT03117998 - Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter